



200 2300
FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: 512/536-3020

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598



June 12, 2003

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 12, 2003

Date

Michael R. Krawzsenek

MS SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/039,171 entitled "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ORGANOPHOSPHATE TOXICITY" – Robert Haley et al.*
Our reference: UTSD:749US
Client reference: UTSMD/DAL:0749

Sir:

Please find enclosed:

- (1) A Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed May 27, 2003;
- (2) Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g);
- (3) Computer Readable Form of Sequence Listing;
- (4) Paper Copy of Sequence Listing;
- (5) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and


25305777.1

Commissioner for Patents
June 12, 2003
Page 2

- (6) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:749US.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898

MRK/mar
Encl: as noted